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ABSTRACT
Original Scientific Article 
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Bronchial and upper respiratory diseases have been associated with hypoxia and subsequent development of pulmonary arterial 
hypertension (PAH). However, there are no known studies assessing the prevalence of PAH in dogs with these conditions. 
The aim of this study was to assess the frequency of PAH in dogs with bronchial and upper respiratory diseases. Medical 
records of dogs with confirmed diagnosis (by endoscopic examination) of bronchial and/or upper respiratory diseases referred 
for cardiovascular investigation (January 2009 - May 2013) were retrospectively reviewed. Diagnosis of PAH was made by 
echocardiography (tricuspid regurgitation > 2.8 m/s and/or pulmonic regurgitation > 2.2 m/s); possible PAH was diagnosed 
when two or more specific echocardiographic findings were present. 52 dogs (30 with upper respiratory diseases, 17 with 
bronchial disease and 5 with both) were included. Diagnosis of PAH was performed in 3 dogs (5.7%). Two dogs were considered 
as probably affected by PAH; a total of 5 dogs (9.4%) resulted in being affected or probably affected by PAH. Our study shows 
that the prevalence of PAH in dogs with bronchial and/or upper respiratory diseases is low; PAH seems to occur mostly in older 
dogs and/or with very advanced disease: echocardiography may therefore be a useful tool in this category of patients. 
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INTRODUCTION
In veterinary medicine, pulmonary arterial 
hypertension (PAH) is defined as pulmonary 
arterial systolic pressure greater than 25 mmHg 
(1). Right-heart catheterization is considered the 
“gold standard” in order to diagnose PAH (2, 3, 
4). However it is rarely performed in veterinary 
medicine (1, 3, 4). In the absence of right ventricular 
(RV) outfl ow tract obstruction (e.g. pulmonary 
stenosis) or significant right-sided volume overload 
(e.g. tricuspid valve dysplasia), pulmonary arterial 
pressure can be inferred non-invasively with 
Doppler echocardiography, either by calculation of 
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the maximal velocity of the regurgitant fl ow across 
the tricuspid (systolic pulmonary arterial pressure) 
or across the pulmonary valve (diastolic pulmonary 
arterial pressure) using the modified Bernoulli 
equation (4, 5, 6).
The severity of PAH is classified as mild, 
moderate, and severe based on the estimated 
pulmonary arterial pressure, with slight variations 
in cut off values among reports, in dogs affected by 
cardiovascular diseases (6, 7, 8).
PAH may occur through three mechanisms: 
increased left atrial pressure, increased pulmonary 
blood flow, and increased pulmonary vascular 
resistance. The pathophysiology of PAH is 
multifactorial and results from an imbalance of 
endogenous and exogenous pulmonary artery 
vasodilators and vasoconstrictors; this disequilibrium 
causes vasoconstriction, vascular smooth muscle 
cell proliferation and thrombosis, leading to an 
increased pulmonary vascular resistance in PAH (9, 
10).
In people, chronic obstructive airway disease 
is one of the most common pulmonary causes of 
PAH (11). Chronic obstructive airway disease may 
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decrease the partial pressure of alveolar oxygen, 
which can result in hypoxia. In contrast to the 
systemic vasculature, which responds to hypoxia 
with vasodilatation to better perfuse hypoxic tissue, 
the pulmonary vasculature responds to hypoxia 
by pulmonic arterial vasoconstriction, which 
subsequently increases the pulmonary pressure (6). 
Few data is available on the PAH prevalence in 
dogs, except for selected conditions such as canine 
heartworm disease, left-sided heart failure and 
Angiostrongylus vasorum infection (12, 13, 14, 15, 
16, 17) 
Recently, some authors evidenced an association 
of pulmonary hypertension and increase serum CRP 
(C-reactive protein) concentrations in dogs affected 
by heartworm disease (12). Interestingly, the CRP 
concentration relates to the severity of endothelial 
arteritis, and not as a result of heartworm disease 
itself (12). The CRP concentration was still high 
even following adulticide treatment, and this 
underlined the possibility that CRP may be used as 
an early biomarker of pulmonary hypertension (12).
In veterinary medicine, lung disease, such 
as chronic pneumonia and lung fibrosis, chronic 
bronchitis, bronchiectasis, and upper respiratory 
disease such as tracheal collapse and laryngeal 
paralysis, have been associated with sustained 
or intermittent hypoxia and subsequent PAH 
development (10). PAH in dogs occurs mostly in 
patients with very advanced disease or those with 
predisposing conditions (9, 10). However, there are 
no known studies assessing the prevalence of PAH 
in dogs with bronchial and/or upper respiratory 
disease. The aim of this study was to assess the 
prevalence of PAH in dogs with bronchial and/or 
upper respiratory disease.
MATERIAL AND METHODS
The medical records of 1,063 dogs referred for 
cardiovascular investigation at the Cardiology Unit 
of the Department of Veterinary Science and Public 
Health between January 2009 and May 2013 were 
retrospectively reviewed. Only first visit cases were 
included in the study.
Inclusion criteria were: complete clinical 
records, radiographic, echocardiographic, a 
confirmed diagnosis by endoscopic examination 
of bronchial and/or upper respiratory disease and 
negative Dirofilaria immitis antigen test. 
Exclusion criteria were: any cardiac and/or 
systemic disease that may cause PAH, except for mild 
mitral valve disease; diagnosis of Angiostrongylus 
vasorum, achieved using a Baermann faecal test 
performed at a veterinary diagnostic laboratory, or 
by detection of L1 larvae on a direct faecal smear or 
bronchoalveolar lavage sample by a trained operator. 
The signalment, clinical history, and clinical signs 
(cough, dyspnoea, syncope, asthenia, weight loss, 
snoring, and reverse sneezing) were recorded.
Echocardiography was performed using an 
ultrasound system (MyLab 50, ESAOTE, Florence, 
Italy) equipped with a phased array transducer 
(7.5−10 MHz for small dogs, 5−7.5 MHz for 
medium dogs, and 2.5−3 MHz for large dogs and 
Doppler studies). Examinations were performed in 
awake dogs in left and right lateral recumbency, 
as recommended by the American Society of 
Echocardiography (18).
Echocardiographic and Doppler Examinations
The following echocardiographic parameters 
were evaluated:
B- and M- modes
1. Presence/absence of RV hypertrophy and/or 
dilation in the right parasternal long axis 4-chamber 
and short axis views at the level of the papillary 
muscle. The RV wall thickness was considered 
increased (RV hypertrophy) if it was greater than 
half the thickness of the left ventricular free wall 
(1). The RV chamber size was considered normal 
if it was smaller than or equal to one-half of the left 
ventricular thickness, mildly enlarged if greater than 
or equal to one-half the left ventricular thickness, or 
severely enlarged if greater than the left ventricle 
(5).
2. Presence/absence of fl at or paradoxical 
interventricular septal motion in the right parasternal 
short axis and/or in M-mode at the level of the 
papillary muscle (10).
3. Presence/absence of main pulmonary 
artery enlargement based on the ratio between the 
diameters of the main pulmonary artery and the 
aorta (PA:AO ratio): a ratio greater than 0.98 was 
considered enlarged (1).
Doppler 
1. Presence/absence of tricuspid regurgitation 
(TR): the TR systolic peak velocity (m/s) and peak 
systolic gradient (mmHg) were measured when 
present.
2. Presence/absence of pulmonic insufficiency 
(PI): the PI diastolic peak velocity (m/s) and peak 
diastolic gradient (mmHg) were measured when 
present. The presence and severity of PI were 
assessed through colour flow mapping, and the 
extension of the regurgitation jet and its width at the 
origin were evaluated (20).
3. Pulmonary artery systolic flow profiles: Type 
I (normal) was defined as a symmetric profile and 
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a rounded systolic peak; type II (mild and moderate 
PAH) as a peak velocity occurring during early 
systole and a long deceleration phase (asymmetric 
profile); and type III (severe PAH) was defined as 
having a notch in the deceleration phase (1).
4. Systolic time intervals: The acceleration time 
(AT), defined as the time to peak pulmonary artery 
fl ow velocity; RV ejection time (ET); and AT:ET 
ratio were assessed  (21).
Doppler flow interrogations of the TR and PI 
jets were used to estimate the systolic and diastolic 
pulmonary arterial pressure respectively, allowing 
diagnosis and quantification of PAH (10). PAH 
was diagnosed when the TR systolic peak velocity 
(m/s) was greater than 2.8 m/s; the TR systolic peak 
velocity (m/s) and peak systolic gradient (mmHg) 
were used to classify the PAH severity (Table 1) 
(1, 4). The presence of PI with a velocity >2.2 m/s 
was considered suggestive of diastolic PAH (1, 4).
Mild Moderate Severe
TR peak systolic velocity (m/s) > 2.8 to< 3.5 3.5 - 4.3 > 4.3
TR systolic gradient (mmHg) > 31.4 a < 50 50 - 75 > 75
Table 1. Classification of pulmonary hypertension based on TR (tricuspid regurgitation) peak systolic velocity and 
TR gradient (1). (TR: tricuspid regurgitation)
If TR/PI were absent, then PAH was considered 
possible when two or more of the following 
echocardiographic findings were recorded: 
1. Presence of RV hypertrophy and/or dilation 
(5, 19)
2. Presence of main pulmonary artery 
enlargement (PA:AO ratio > 0.98) (1)
3. Presence of type II or III pulmonary artery 
systolic flow profile (1)
4. AT:ET < 0.31 and/or AT < 58 ms (21)
Endoscopic examination
Endoscopy was performed using either a rigid 
instrument equipped with a 18-cm optical length, 
2.7-mm thickness, (Karl Storz Hopkins II, Dr. 
Karl-Storz-Straße 34 Tuttlingen, Germany), 1-ccd 
camera (Wolf Endocam 551, Pforzheimer-Straße 
32, 75438 Knittlingen, Germany),and xenon 
light source (Storz Xenon Nova 20131520, Dr. 
Karl-Storz-Straße 34 Tuttlingen, Germany) for 
examination of the nasal cavity, or a flexible video 
endoscope (4.9-mm diameter and 2-mm channel 
size, Fujinon Videobronchoscope EB-270 S7-3, 
Akasaka 9-chome, Minato-ku, Tokyo 107-0052, 
Japan) for examination of other respiratory airways.
Statistical analysis
The Shapiro–Wilk test was used to verify 
normal distribution. Normally distributed data 
were expressed as the mean ± standard deviation. 
For data not normally distributed, the median and 
interquartile (IQR (25th to 75th percentile)) were 
calculated. Data were analyzed using statistical 
software (JMP version 7, JMP Headquarters, SAS 
Institute, Cary, NC, USA 27513).
RESULTS
Fifty-two clinical records fulfilled the inclusion 
criteria (35 males and 17 females), and represented 
4.9 % of the total referral patients seen at the 
Cardiology Unit of the Department of Veterinary 
Science and Public Health between January 2009 
and May 2013.  Fourteen breeds were represented: 
10 English Bulldogs (19%) resulted the prevalent, 
7 males (70%) and 3 females (3%), followed by 
8 crossbreeds dogs (15%), 5 males (62.5%) and 
3 females (37.5%), 8 French Bulldogs (15%), 
7 males (87.5%) and 1 female (12.5%) and 6 
Yorkshire Terriers (11%), 2 males (33.3%) and 4 
females (66.6%). The age ranged from 0.8 to 16 
years (median 7 years; IQR: 3−12.25 years) and 
the weight from 2 to 40 kg (median 12 kg; IQR: 
7.35−18 kg). All dogs showed at least one clinical 
sign: cough (50.1%), dyspnoea (50.1%), snoring 
(30.1%), exercise intolerance (15%), weight loss 
(9.4%), reverse sneeze (5.2%), and syncope (5.6%). 
Twenty-eight dogs (54%) showed more than one 
clinical sign simultaneously. The most common 
associations of symptoms were cough, dyspnoea and 
exercise intolerance (10.7%), cough and dyspnoea 
(21.4%), dyspnoea and snoring (10.7%).
Endoscopic examination
Seventeen dogs (33%; 8 females and 9 males) 
were diagnosed with bronchial disease (9 chronic 
bronchitis, 6 chronic bronchitis and bronchial 
collapse, 2 bronchial collapse). The prevalence on 
the total population referred was 1.6 %. Crossbreed 
dogs were the most represented (39%); the age 
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ranged from 1 to 15 years (median 12 years ; IQR: 
11−13 years) and the weight from 3 to 16 kg (median 
8 kg; IQR: 4−13.25 kg).
Thirty dogs (56.6%; 8 females and 22 males) were 
diagnosed with upper respiratory disease. Twenty-
one of them resulted affected by brachycephalic 
airway obstructive syndrome (BAOS) (70 %; 5 
female and 16 male), 3 by laryngeal paralysis, 2 
by tracheal collapse, and 1 by laryngeal collapse; 
3 dogs exhibited multiple upper respiratory disease 
simultaneously. The prevalence on the total 
population referred was 2.8 %. The most represented 
breeds were English and French Bulldogs (57%). 
The age ranged from 0.8 to 16 years (median 3.5 
years; IQR: 3−10.25 years), and the weight ranged 
from 2 to 40 kg (median 13.85 kg; IQR: 10−21 kg). 
In the BAOS group specifically, the age ranged from 
0.11 to 12 years (median 3 years; IQR: 2−4 years) 
and the weight from 8 to 26 kg (median 14 kg; IQR: 
12−21 kg). Five dogs (9.5%; 1 female and 4 males), 
exhibited upper respiratory disease and bronchial 
disease simultaneously, 0.5 % the pre valence of 
this group on the total population referred to the 
Cardiology Unit during the study time. 
Echocardiographic data
Mild RV enlargement was found in 4 dogs 
(7.5%) and mild RV hypertrophy in 2 dogs (3.8%). 
Table 2. Signalment, clinical signs, echocardiographic and Doppler data, PAH severity and endoscopic diagnosis of 
5 dogs affected by PAH. (F: female; M: male; TR: tricuspid regurgitation) 
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1 Poodle M 11 Dyspnea 3.76 56.60 - Normal Moderate
Upper 
Respiratory 
Diseases
Laryngeal 
collapse and 
paralysis
2 Crossbreed F 11
Cough  
and 
dyspnea
4.02 64.60 Mild Normal Moderate
Upper 
Respiratory 
Diseases
Tracheal 
collapse
3 French Bulldog M 7 Weight loss 2.99 35.7 Mild Normal Mild
Upper 
Respiratory 
Diseases
Palatal 
disease
4 Yorkshire Terrier F 5 Cough - - Mild Type II Possible
Upper 
Respiratory 
Diseases
Tracheal 
collapse
5 Poodle F 12 Cough - - Mild Type II Possible Bronchial Diseases
Chronic 
bronchitis
One dog (1.9%) exhibited both RV hypertrophy and 
dilation simultaneously. No dog presented flat or 
paradoxical interventricular septal motion or main 
pulmonary artery enlargement.
TR was observed  in 15 dogs (29%). The TR 
peak systolic velocity ranged from 1.51 m/s to 4.02 
m/s (mean 2.62 ± 0.71 m/s), and the TR systolic 
gradient ranged from 9.10 mmHg to 64.60 mmHg 
(median 23.90 mmHg; IQR: 17.88−30.15 mmHg).
No dog showed pulmonary insufficiency. Type 
II pulmonary artery systolic flow profile was found 
in 2 dogs (3.8%) and was associated with mild RV 
hypertrophy in both. No dog presented an AT: ET 
ratio equal to or less than 0.31, and none exhibited 
an AT equal to or less than 58 ms. The mean AT: 
ET ratio was 0.48 ± 0.04, and the mean AT was 
83.08±14.24 ms.
PAH was diagnosed in 3 dogs (5.7%) based 
on a TR peak systolic velocity >2.8 m/s. All three 
dogs were diagnosed with upper respiratory disease; 
therefore, the prevalence of PAH in this subgroup 
was 10%. Two dogs (one with bronchial disease 
and one with upper respiratory pathology) were 
considered likely to have PAH based on the presence 
of secondary specific echocardiographic findings. A 
total of 5 dogs (9.4%) had confirmed or probable 
PAH (Table 2), the prevalence in the overall referral 
population being  0.5 % and  1 % of dogs with 
valvular disease.
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DISCUSSION
PAH is a well-recognized clinical condition in 
humans. Conversely, few data are available in dogs, 
except for PAH secondary to canine heartworm 
disease, mitral valve disease and Angiostrongylus 
vasorum infection (1, 6, 8, 9, 14, 15,16, 17, 22, 
23, 24). The degree of hypoxia that can cause 
PAH likely exists in a large number of dogs with 
both upper and lower airway obstructive diseases 
(9). In particular, lung disease, such as chronic 
pneumonia, lung fibrosis, chronic bronchitis, 
bronchiectasis, and upper respiratory pathologies, 
such as tracheal collapse and laryngeal paralysis, 
have been associated with sustained or intermittent 
hypoxia and have been thought as theoretically 
causing PAH (5, 9, 10). Nevertheless, there are no 
known studies assessing the prevalence of PAH in 
dogs with respiratory disease, except for one study 
of West Highland White terriers, in which PAH 
occurred in more than 49% of dogs diagnosed with 
chronic interstitial pulmonary disease (19).
In humans, the prevalence of PAH in patients 
with at least one previous hospitalization for 
exacerbation of respiratory failure is 20%, and 
in patients with advanced respiratory disease, 
the prevalence is higher (>50%), although the 
severity is usually mild (2). In our population, the 
prevalence of PAH in dogs with bronchial and/
or upper respiratory diseases associated with 
potential hypoxia was low (5 dogs, 9.4%), even 
when both confirmed and possible PAH cases were 
considered, or very low (3 dogs, 5.7%) when only 
PAH diagnosed by TR velocity was considered. All 
3 dogs with confirmed PAH were diagnosed with 
upper respiratory disease; therefore, the occurrence 
of PAH in this disease category was slightly high 
(3/30, 10%). Only mild and moderate PAH was 
identified.
In dogs with upper respiratory disease, PAH 
or possible PAH was diagnosed in 2 dogs with 
tracheal collapse, 1 dog with laryngeal collapse and 
paralysis, and 1 dog with BAOS (Table 2). Three 
of four dogs were older than the median age for 
the group (3.5 years); the only young dog showed 
echocardiographic signs of possible PAH and 
was diagnosed with very severe cervical tracheal 
collapse (Table 2). The occurrence of PAH in dogs 
with BAOS was also very low (1/21), though most of 
the dogs included in the study were young (median 
age 3 years). Interestingly, the only dog with BAOS 
(Table 2) diagnosed with PAH was older (7 years) 
than the rest of dogs with BAOS included in this 
study. Based on these results, we speculate that 
early surgical correction may be protective from 
PAH, but further studies are needed to confirm this 
hypothesis. 
In our cases series, only one dog with bronchial 
disease presented echocardiographic signs 
suggesting possible PAH, and no dog with bronchial 
disease exhibited PAH. We found these data 
relatively surprising because chronic hypoxemia 
and increased airway resistance have been described 
as common findings in patients with advanced 
chronic bronchitis, and cor pulmonale is considered 
a possible consequence (25). The low occurrence 
of PAH in dogs with bronchial disease and in all 
dogs in our study may be due to the relatively poor 
vasoconstrictive response to hypoxia exhibited by 
dogs compared with other species (9, 10). Canine 
PAH seems to occur mostly during very advanced 
respiratory disease, as described in West Highland 
White terriers and suggested by several reports (9, 
21).
Based on our results, we recommend an 
echocardiographic investigation only in older dogs 
with bronchial and/or upper respiratory disease or 
in dogs with advanced disease regardless of age. 
Echocardiographic and spectral Doppler assessments 
of tricuspid and pulmonic regurgitation are useful 
tool in this group of patients especially when 
utilized as a part of comprehensive assessment of 
PAH, and may supplement the methods traditionally 
used to investigate the respiratory system in canine 
patients (3, 26).
Diagnosis of PAH was based only on 
echocardiographic data: a TR systolic peak velocity 
greater than 2.8 m/s, a PI diastolic peak velocity 
greater than 2.2 m/s, the presence of a type II or 
III pulmonary artery systolic flow profile, and the 
presence of RV hypertrophy/dilation (4). Pulmonary 
hypertension was then classified as mild, moderate, 
and severe based on the tricuspid regurgitation peak 
systolic velocity and gradient. None of the dogs 
exhibited severe PAH; two dogs had moderate PAH, 
one mild, and two possible PAH. Potentially, some 
cases of PAH in our study population may have been 
undetectable using echocardiography (3). Cardiac 
catheterization is the “gold standard” to diagnose 
PAH, but in veterinary medicine, right heart 
catheterization is often considered unacceptably 
invasive by the clinician in a compromised patient, 
therefore the echocardiographic and spectral Doppler 
approach remains very common in clinical practice 
(3). When available however, catheterization 
enables measurement of multiple hemodynamic 
parameters that assist in the diagnosis and etiologic 
classification of PAH (1).
None of the dogs exhibited flat or paradoxic 
interventricular septal motion, main pulmonary artery 
enlargement, an AT: ET ≤ 0.31, or an AT ≤ 58 ms.
These findings may be because very few dogs were 
diagnosed with PAH, and when present, PAH was 
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mild or moderate, with no cases of severe PAH 
diagnosed. A median AT: ET of 0.48 and a median 
AT of 83 ms suggested a normal pulmonary pressure 
in the population and agree with previously reported 
values in healthy West Highland White terriers, 
which had a median AT:ET of 0.40 and a median AT 
of 73 ms (21).
None of the dogs with PAH presented syncope or 
exercise intolerance. The dogs with PAH included 
in our study only showed respiratory signs, with 
cough and dyspnoea as the most common clinical 
signs. These particular clinical signs likely refl ect 
the underlying bronchial and/or upper respiratory 
disease causing PAH.
The epidemiological characteristics of our 
population agree with those previously reported, 
namely young English and French Bulldogs with 
BAOS, older large breed dogs (Labrador and Setter) 
with laryngeal paralysis, Yorkshire Terrier, typically 
middle-aged, with tracheal collapse, and older small 
breed dogs with chronic bronchitis (5, 27, 28, 29, 
30).
This study has a number of limitations as a 
result of its retrospective nature. We only used 
non-invasive diagnostic approaches, and cardiac 
catheterization was not performed. PAH was 
diagnosed based only on certain echocardiographic 
and Doppler parameters (TR systolic peak velocity 
greater than 2.8 m/s, PI diastolic peak velocity 
greater than 2.2 m/s, presence of a type II or III 
pulmonary artery systolic flow profile, and presence 
of RV hypertrophy/dilation), and several parameters 
were not measured, including the TEI index and 
TAPSE (tricuspid annular plane systolic excursion). 
Moreover the lack of arterial blood-gas data could 
be an additional weakness in this study. Only cases 
with endoscopic diagnosis of bronchial and/or upper 
respiratory diseases were included; no parenchymal 
diseases, nor pleural diseases were included in our 
study. 
Finally, most of the dogs diagnosed with BAOS 
were young and West Highland White terriers, 
a breed predisposed to PAH secondary to severe 
lung disease, was not included in the study (21). 
In conclusion, our study shows that the occurrence 
of PAH in dogs with bronchial and/or upper 
respiratory disease is low; PAH seems to occur 
mostly in older dogs or those with very advanced 
disease. The echocardiographic and spectral 
Doppler assessments of tricuspid and pulmonic 
regurgitation are useful tool in these classes of 
patients. Nevertheless, further prospective studies 
including different subsets of pathologies, clinical 
settings (acute vs chronic), disease severity (mild/
moderate/severe) and the evaluation of clinical 
biomarkers (i.e. C-reactive protein) are needed to 
confirm these results.
Ethical approval
All applicable international, national, and 
institutional guidelines for the care and use of 
animals were followed. All procedures performed in 
studies involving animals were in accordance with 
the ethical standards of the institution or practice at 
which the studies were conducted. For this type of 
study, formal consent was not required.
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